制药巨头美股盘前大涨50%！公司达成57亿美元许可交易

Group 1 - Swiss pharmaceutical giant Novartis has signed a licensing agreement worth up to $5.7 billion with biotechnology company Monte Rosa for the development of drugs to treat immune-mediated diseases [1] - Monte Rosa will receive an upfront payment of $120 million as part of the agreement [1] - Following the announcement, Monte Rosa's stock surged by 50% in pre-market trading [1]